Vir Biotechnology 거래 VIR

VirBiotechnology 실시간 차트

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

최신 뉴스

더 보기
Sophia Claire 2025 Aug 11, 14:20

Indian Rupee Under Pressure: RBI Intervenes Amid Trade Tensions

Noah Lee 2025 Aug 11, 10:04

Israeli Minister Doubts Netanyahu's Ability to Achieve 'Decisive Victory' in Gaza

2025 Aug 11, 09:20

Trump-Putin Talks Spark Rally in Ukraine, Russia-Linked Assets

2025 Aug 11, 09:20

Europe Urges US to Ramp Up Russia Sanctions Before Trump-Putin Meeting

Sophia Claire 2025 Aug 11, 01:20

US Treasury Chief: Tariffs, Trade Imbalance, and the Fed's Future

Tommy Yap 2025 Aug 10, 21:00

Morning Note: Gold Dips; Wall Street Rallies; Fed Chair Qualifications Outlined

Morning Note Gold Stocks Economic Data Central Banks
Ghko B 2025 Aug 10, 16:00

Stock market news: META stock surged on AI-powered ad growth

Stocks
Tommy Yap 2025 Aug 09, 21:00

Week Ahead: RBA interest rate decision and US CPI data in focus

Forex Indices

정보

스프레드

0.03

스프레드(%)

0.7026 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

월요일

13:31 - 19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

597338816

발행 주식 수

138916000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-4.01

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

더 보기
Trustpilot